SG11201804484YA - Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy - Google Patents
Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathyInfo
- Publication number
- SG11201804484YA SG11201804484YA SG11201804484YA SG11201804484YA SG11201804484YA SG 11201804484Y A SG11201804484Y A SG 11201804484YA SG 11201804484Y A SG11201804484Y A SG 11201804484YA SG 11201804484Y A SG11201804484Y A SG 11201804484YA SG 11201804484Y A SG11201804484Y A SG 11201804484YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- chemotherapy
- dompe
- treatment
- induced
- Prior art date
Links
- 238000002512 chemotherapy Methods 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 3
- 241000272478 Aquila Species 0.000 abstract 2
- 102000004890 Interleukin-8 Human genes 0.000 abstract 2
- 108090001007 Interleukin-8 Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 abstract 1
- 108010018976 Interleukin-8A Receptors Proteins 0.000 abstract 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 abstract 1
- 102000002791 Interleukin-8B Receptors Human genes 0.000 abstract 1
- 206010061323 Optic neuropathy Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000020911 optic nerve disease Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 11111 01110111010111111 OM 10111110H III International Bureau .. .... ..Yejd .... ...,,, (10) International Publication Number (43) International Publication Date WO 2017/121838 Al 20 July 2017 (20.07.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/165 (2006.01) A61P 25/02 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/19 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP2017/050637 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 13 January 2017 (13.01.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 16151618.2 15 January 2016 (15.01.2016) EP (84) Designated States (unless otherwise indicated, for every 16190871.0 27 September 2016 (27.09.2016) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: DOMPE' FARMACEUTICI S.P.A. [IT/IT]; TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Via San Martino della Battaglia, 12, 1-20122 Milano (MI) TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (IT). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: BRANDOLINI, Laura; c/o Dompe farmaceut- ici S.p.A., Via Campo Di Pile s.n.c., 1-67100 L'Aquila SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (AQ) (IT). RUFFINI, Pieradelchi; c/o Dompe farmaceut- — ici S.p.A., Via Campo Di Pile s.n.c., 1-67100 L'Aquila Declarations under Rule 4.17: — = (AQ) (IT). ALLEGRETTI, Marcello; c/o Dompe farma- - ceutici S.p.A., Via Campo Di Pile s.n.c., 1-67100 L'Aquila of inventorship (Rule 4.17(iv)) = (AQ) (IT). Published: (74) Agents: PISTOLESI, Roberto et al.; Via Nino Bixio, 7, I- — with international search report (Art. 21(3)) 20129 Milano MI (IT). = = (54) Title: IL-8 INHIBITORS FOR USE IN - PATHY = = Fig. 1 = = = = 50 = _ _ -53 40- . .. _ O9 30 , - 1 i 26 GC 1 er) st- %- GC 11 ei a 1 THE TREATMENT xxx 1 OF .44 - 1¢ I 11 RA. CHEMOTHERAPY E3 IIIII CM Mt. 4' -INDUCED PERIPHERAL NEURO- SHAM CONTROL DF2627A-TREATED 1-1 -1 5 1 10 14 IN Day 1-1 N (57) : The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1 /CXCR2 receptor inhibitors, use- ful in the treatment and/or prevention of chemotherapy-induced neuropathy, preferably in the treatment and/or prevention of chemo - Q therapy-induced peripheral neuropathy (CIPN) or chemotherapy-induced optic neuropathy.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16151618.2A EP3192504A1 (en) | 2016-01-15 | 2016-01-15 | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
| EP16190871 | 2016-09-27 | ||
| PCT/EP2017/050637 WO2017121838A1 (en) | 2016-01-15 | 2017-01-13 | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804484YA true SG11201804484YA (en) | 2018-07-30 |
Family
ID=57906595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804484YA SG11201804484YA (en) | 2016-01-15 | 2017-01-13 | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20190015391A1 (en) |
| EP (1) | EP3402474B1 (en) |
| JP (1) | JP7049254B2 (en) |
| KR (1) | KR20180101390A (en) |
| CN (1) | CN108463219B (en) |
| AU (1) | AU2017207850B2 (en) |
| CA (1) | CA3009438A1 (en) |
| CY (1) | CY1125297T1 (en) |
| DK (1) | DK3402474T3 (en) |
| ES (1) | ES2893701T3 (en) |
| HR (1) | HRP20211527T1 (en) |
| HU (1) | HUE056606T2 (en) |
| IL (1) | IL260373B (en) |
| LT (1) | LT3402474T (en) |
| MA (1) | MA43861A (en) |
| MX (1) | MX2018008614A (en) |
| PL (1) | PL3402474T3 (en) |
| RS (1) | RS62427B1 (en) |
| SG (1) | SG11201804484YA (en) |
| SI (1) | SI3402474T1 (en) |
| WO (1) | WO2017121838A1 (en) |
| ZA (1) | ZA201803486B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101914358B1 (en) * | 2017-01-18 | 2018-11-02 | 현대로템 주식회사 | Circuit for controlling room lamp and railroad train having the same |
| CN111343973A (en) * | 2017-10-24 | 2020-06-26 | 多姆皮制药公司 | IL-8 inhibitors for the treatment of certain sarcomas |
| EP3476390A1 (en) | 2017-10-24 | 2019-05-01 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of sarcomas |
| EP3498269A1 (en) * | 2017-12-12 | 2019-06-19 | Dompé farmaceutici S.p.A. | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1303249B1 (en) | 1998-10-23 | 2000-11-06 | Dompe Spa | SOME N- (2-ARYL-PROPIONYL) -SULPHONAMIDS AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM. |
| AU2005223402B2 (en) * | 2004-03-23 | 2011-07-21 | Dompe' Farmaceutici S.P.A. | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them |
| EP2066335A4 (en) | 2006-09-26 | 2010-01-20 | Univ Case Western Reserve | Cytokine signaling |
| EP2166006A1 (en) | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| CR20160557A (en) | 2014-05-29 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | COMPOUNDS DERIVED FROM 1- (CICLOPENT-2-EN-1-IL) -3- (2-HIDROXI-3- (ARILSULFONIL) PHENYL) UREA AS CXCR2 INHIBITORS |
| CA2956785A1 (en) * | 2014-07-31 | 2016-02-04 | Glaxosmithkline Intellectual Property Development Limited | Use of cxcr2 antagonists for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (cipn) |
-
2017
- 2017-01-13 RS RS20211209A patent/RS62427B1/en unknown
- 2017-01-13 WO PCT/EP2017/050637 patent/WO2017121838A1/en active Application Filing
- 2017-01-13 AU AU2017207850A patent/AU2017207850B2/en active Active
- 2017-01-13 HU HUE17701646A patent/HUE056606T2/en unknown
- 2017-01-13 DK DK17701646.6T patent/DK3402474T3/en active
- 2017-01-13 LT LTEPPCT/EP2017/050637T patent/LT3402474T/en unknown
- 2017-01-13 HR HRP20211527TT patent/HRP20211527T1/en unknown
- 2017-01-13 EP EP17701646.6A patent/EP3402474B1/en active Active
- 2017-01-13 CN CN201780005946.9A patent/CN108463219B/en active Active
- 2017-01-13 MX MX2018008614A patent/MX2018008614A/en unknown
- 2017-01-13 ES ES17701646T patent/ES2893701T3/en active Active
- 2017-01-13 JP JP2018537469A patent/JP7049254B2/en active Active
- 2017-01-13 SG SG11201804484YA patent/SG11201804484YA/en unknown
- 2017-01-13 PL PL17701646T patent/PL3402474T3/en unknown
- 2017-01-13 KR KR1020187019923A patent/KR20180101390A/en not_active Application Discontinuation
- 2017-01-13 US US16/066,072 patent/US20190015391A1/en active Pending
- 2017-01-13 SI SI201730924T patent/SI3402474T1/en unknown
- 2017-01-13 CA CA3009438A patent/CA3009438A1/en active Pending
- 2017-01-13 MA MA043861A patent/MA43861A/en unknown
-
2018
- 2018-05-25 ZA ZA2018/03486A patent/ZA201803486B/en unknown
- 2018-07-02 IL IL260373A patent/IL260373B/en active IP Right Grant
-
2021
- 2021-10-14 CY CY20211100886T patent/CY1125297T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017207850A1 (en) | 2018-06-21 |
| KR20180101390A (en) | 2018-09-12 |
| SI3402474T1 (en) | 2021-12-31 |
| CN108463219B (en) | 2021-09-17 |
| CY1125297T1 (en) | 2023-03-24 |
| DK3402474T3 (en) | 2021-10-11 |
| PL3402474T3 (en) | 2021-12-27 |
| WO2017121838A1 (en) | 2017-07-20 |
| CA3009438A1 (en) | 2017-07-20 |
| CN108463219A (en) | 2018-08-28 |
| MA43861A (en) | 2021-05-05 |
| MX2018008614A (en) | 2018-11-19 |
| RS62427B1 (en) | 2021-11-30 |
| EP3402474B1 (en) | 2021-07-21 |
| EP3402474A1 (en) | 2018-11-21 |
| AU2017207850B2 (en) | 2022-06-30 |
| ZA201803486B (en) | 2019-09-25 |
| ES2893701T3 (en) | 2022-02-09 |
| BR112018013570A2 (en) | 2018-12-11 |
| HRP20211527T1 (en) | 2021-12-24 |
| HUE056606T2 (en) | 2022-02-28 |
| US20190015391A1 (en) | 2019-01-17 |
| IL260373B (en) | 2021-03-25 |
| JP7049254B2 (en) | 2022-04-06 |
| JP2019501948A (en) | 2019-01-24 |
| LT3402474T (en) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201809024UA (en) | Cancer immunotherapy by immune activation or immune modulation via globo series antigens | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201804484YA (en) | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis |